UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Clinical cancer research, 2019-04, Vol.25 (7), p.2174-2184

2019

Volltextzugriff (PDF)

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2005-01, Vol.23 (1), p.133-141

2005

Volltextzugriff (PDF)

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Journal of clinical oncology, 2004-03, Vol.22 (5), p.909-918

2004

Volltextzugriff (PDF)

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1029-1039

2021

Volltextzugriff (PDF)

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1020-1028

2021

Volltextzugriff (PDF)

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Journal of clinical oncology, 2020-09, Vol.38 (27), p.3088-3094

2020

Volltextzugriff (PDF)

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

Journal of clinical oncology, 2015-06, Vol.33 (18), p.2013-2020

2015

Volltextzugriff (PDF)

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

Urologic oncology, 2013-11, Vol.31 (8), p.1788-1793

2013

Volltextzugriff (PDF)

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

Journal of clinical oncology, 2015-07, Vol.33 (21), p.2384-2391

2015

Volltextzugriff (PDF)

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

JAMA oncology, 2017-09, Vol.3 (9), p.1249

2017

Volltextzugriff (PDF)

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

Clinical cancer research, 2015-09, Vol.21 (18), p.4048-4054

2015

Volltextzugriff (PDF)

Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer

Clinical cancer research, 2007-04, Vol.13 (7), p.2100-2108

2007

Volltextzugriff (PDF)

Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma

Radiology, 2021-02, Vol.298 (2), p.332-340

2021

Volltextzugriff (PDF)

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study

Journal of clinical oncology, 2015-10, Vol.33 (30), p.3431-3438

2015

Volltextzugriff (PDF)

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma

Cancer, 2016-01, Vol.122 (1), p.124-130

2016

Volltextzugriff (PDF)

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Cancer, 2019-07, Vol.125 (14), p.2400-2408

2019

Volltextzugriff (PDF)

Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak

Clinical cancer research, 2007-04, Vol.13 (7), p.2115-2120

2007

Volltextzugriff (PDF)

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Clinical cancer research, 2007-06, Vol.13 (11), p.3312-3319

2007

Volltextzugriff (PDF)

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy

BJU international, 2010-09, Vol.106 (6), p.772-778

2010

Volltextzugriff (PDF)

Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-γ Induction Is Associated with Clinical Response

Clinical cancer research, 2000-05, Vol.6 (5), p.1678

2000

Volltextzugriff (PDF)

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma

Urologic oncology, 2011-11, Vol.29 (6), p.756-763

2011

Volltextzugriff (PDF)

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma

Clinical genitourinary cancer, 2016-08, Vol.14 (4), p.304-313.e6

2016

Volltextzugriff (PDF)

Phase II Trial of Carboplatin and Paclitaxel in Papillary Renal Cell Carcinoma

Clinical genitourinary cancer, 2009, Vol.7 (1), p.39-42

2009

Volltextzugriff (PDF)

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12

Journal of immunotherapy, 2001-01, Vol.24 (1), p.91-98

2001

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

KollektionAUTh Library subscriptions: Taylor & Francis Journals

KollektionApplied Social Sciences Index & Abstracts (ASSIA)

Zeitschrift / SerieCancer Immunology Research

ThemaImmunotherapy

ThemaAged

ThemaFemale

ThemaKidney Neoplasms - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

Humans
(27)
Male
(27)
Carcinoma, Renal Cell - Drug Therapy
(26)
Life Sciences & Biomedicine
(26)
Middle Aged
(26)
Science & Technology
(26)
Oncology
(24)
Adult
(20)
Kidney Neoplasms - Pathology
(13)
Carcinoma, Renal Cell - Pathology
(11)
Aged, 80 And Over
(10)
Biological And Medical Sciences
(7)
Dose-Response Relationship, Drug
(7)
Medical Sciences
(7)
Prognosis
(7)
Treatment Outcome
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)

12 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer

Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy

Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-γ Induction Is Associated with Clinical Response

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma

Phase II Trial of Carboplatin and Paclitaxel in Papillary Renal Cell Carcinoma

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12

Aktive Filter

Suchergebnisse filtern